BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, Luscieti S, Nai A, Arosio P. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood. 2011;117:997-1004. [PMID: 21076043 DOI: 10.1182/blood-2010-06-289082] [Cited by in Crossref: 94] [Cited by in F6Publishing: 95] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Sebastiani G, Wilkinson N, Pantopoulos K. Pharmacological Targeting of the Hepcidin/Ferroportin Axis. Front Pharmacol 2016;7:160. [PMID: 27445804 DOI: 10.3389/fphar.2016.00160] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 9.5] [Reference Citation Analysis]
2 Vela D. Systemic and local hepcidin as emerging and important peptides in renal homeostasis and pathology. Biofactors 2019;45:118-34. [PMID: 30461080 DOI: 10.1002/biof.1468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
3 Asperti M, Denardo A, Gryzik M, Arosio P, Poli M. The role of heparin, heparanase and heparan sulfates in hepcidin regulation. Vitam Horm 2019;110:157-88. [PMID: 30798810 DOI: 10.1016/bs.vh.2019.01.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Cullis JO. Diagnosis and management of anaemia of chronic disease: current status: Review. British Journal of Haematology 2011;154:289-300. [DOI: 10.1111/j.1365-2141.2011.08741.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 52] [Article Influence: 6.7] [Reference Citation Analysis]
5 Kroot JJ, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: diagnostic implications. Clin Chem. 2011;57:1650-1669. [PMID: 21989113 DOI: 10.1373/clinchem.2009.140053] [Cited by in Crossref: 153] [Cited by in F6Publishing: 148] [Article Influence: 13.9] [Reference Citation Analysis]
6 Kawabata H, Uchiyama T, Sakamoto S, Kanda J, Oishi S, Fujii N, Tomosugi N, Kadowaki N, Takaori-Kondo A. A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol 2015;43:404-413.e5. [PMID: 25633564 DOI: 10.1016/j.exphem.2015.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematology Am Soc Hematol Educ Program 2011;2011:538-42. [PMID: 22160086 DOI: 10.1182/asheducation-2011.1.538] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 7.6] [Reference Citation Analysis]
8 Brkljacic J, Pauk M, Erjavec I, Cipcic A, Grgurevic L, Zadro R, Inman GJ, Vukicevic S. Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity. Int Orthop 2013;37:529-41. [PMID: 23307015 DOI: 10.1007/s00264-012-1714-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
9 Abreu R, Giri P, Quinn F. Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis. Front Immunol 2020;11:1553. [PMID: 32849525 DOI: 10.3389/fimmu.2020.01553] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Colucci S, Marques O, Altamura S. 20 years of Hepcidin: How far we have come. Semin Hematol 2021;58:132-44. [PMID: 34389105 DOI: 10.1053/j.seminhematol.2021.05.001] [Reference Citation Analysis]
11 Asperti M, Stuemler T, Poli M, Gryzik M, Lifshitz L, Meyron-Holtz EG, Vlodavsky I, Arosio P. Heparanase Overexpression Reduces Hepcidin Expression, Affects Iron Homeostasis and Alters the Response to Inflammation. PLoS One 2016;11:e0164183. [PMID: 27711215 DOI: 10.1371/journal.pone.0164183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
12 Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am 2014;28:671-81, vi. [PMID: 25064707 DOI: 10.1016/j.hoc.2014.04.005] [Cited by in Crossref: 205] [Cited by in F6Publishing: 178] [Article Influence: 25.6] [Reference Citation Analysis]
13 Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014;35:155-161. [PMID: 24552640 DOI: 10.1016/j.tips.2014.01.004] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 10.9] [Reference Citation Analysis]
14 Gangat N, Wolanskyj AP. Anemia of Chronic Disease. Seminars in Hematology 2013;50:232-8. [DOI: 10.1053/j.seminhematol.2013.06.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
15 Denardo A, Elli S, Federici S, Asperti M, Gryzik M, Ruzzenenti P, Carmona F, Bergese P, Naggi A, Arosio P, Poli M. BMP6 binding to heparin and heparan sulfate is mediated by N-terminal and C-terminal clustered basic residues. Biochim Biophys Acta Gen Subj 2021;1865:129799. [PMID: 33232799 DOI: 10.1016/j.bbagen.2020.129799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Qian Y, Zhang S, Guo W, Ma J, Chen Y, Wang L, Zhao M, Liu S. Polychlorinated Biphenyls (PCBs) Inhibit Hepcidin Expression through an Estrogen-Like Effect Associated with Disordered Systemic Iron Homeostasis. Chem Res Toxicol 2015;28:629-40. [DOI: 10.1021/tx500428r] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
17 Guan Y, An P, Zhang Z, Zhang F, Yu Y, Wu Q, Shi Y, Guo X, Tao Y, Wang F. Screening identifies the Chinese medicinal plant Caulis Spatholobi as an effective HAMP expression inhibitor. J Nutr 2013;143:1061-6. [PMID: 23700338 DOI: 10.3945/jn.113.174201] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
18 Houamel D, Ducrot N, Lefebvre T, Daher R, Moulouel B, Sari MA, Letteron P, Lyoumi S, Millot S, Tourret J, Bouvet O, Vaulont S, Vandewalle A, Denamur E, Puy H, Beaumont C, Gouya L, Karim Z. Hepcidin as a Major Component of Renal Antibacterial Defenses against Uropathogenic Escherichia coli. J Am Soc Nephrol. 2016;27:835-846. [PMID: 26293821 DOI: 10.1681/asn.2014101035] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.1] [Reference Citation Analysis]
19 Zhang SP, Wang Z, Wang LX, Liu SJ. AG490: An inhibitor of hepcidin expression in vivoWorld J Gastroenterol 2011; 17(45): 5032-5034 [PMID: 22174555 DOI: 10.3748/wjg.v17.i45.5032] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
20 Poli M, Anower-E-Khuda F, Asperti M, Ruzzenenti P, Gryzik M, Denardo A, Gordts PLSM, Arosio P, Esko JD. Hepatic heparan sulfate is a master regulator of hepcidin expression and iron homeostasis in human hepatocytes and mice. J Biol Chem 2019;294:13292-303. [PMID: 31315930 DOI: 10.1074/jbc.RA118.007213] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
21 Poli M, Asperti M, Ruzzenenti P, Mandelli L, Campostrini N, Martini G, Di Somma M, Maccarinelli F, Girelli D, Naggi A, Arosio P. Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. Biochemical Pharmacology 2014;92:467-75. [DOI: 10.1016/j.bcp.2014.09.007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
22 Santos-Silva A, Ribeiro S, Reis F, Belo L. Hepcidin in chronic kidney disease anemia. Vitam Horm 2019;110:243-64. [PMID: 30798815 DOI: 10.1016/bs.vh.2019.01.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
23 Vela D. The Dual Role of Hepcidin in Brain Iron Load and Inflammation. Front Neurosci 2018;12:740. [PMID: 30374287 DOI: 10.3389/fnins.2018.00740] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
24 Chow JKL, Ganz T, Ruthazer R, Simpson MA, Pomfret EA, Gordon FD, Westerman ME, Snydman DR. Iron-related markers are associated with infection after liver transplantation. Liver Transpl. 2017;23:1541-1552. [PMID: 28703464 DOI: 10.1002/lt.24817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
25 Mu M, Wu A, An P, Du X, Wu Q, Shen X, Wang F. Black soyabean seed coat extract regulates iron metabolism by inhibiting the expression of hepcidin. Br J Nutr 2014;111:1181-9. [PMID: 24387766 DOI: 10.1017/S0007114513004005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
26 Vela D, Vela-Gaxha Z. Differential regulation of hepcidin in cancer and non-cancer tissues and its clinical implications. Exp Mol Med 2018;50:e436. [PMID: 29391539 DOI: 10.1038/emm.2017.273] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
27 Poli M, Asperti M, Naggi A, Campostrini N, Girelli D, Corbella M, Benzi M, Besson-Fournier C, Coppin H, Maccarinelli F, Finazzi D, Arosio P. Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood 2014;123:1564-73. [PMID: 24398330 DOI: 10.1182/blood-2013-07-515221] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
28 de Swart L, Reiniers C, Bagguley T, van Marrewijk C, Bowen D, Hellström-Lindberg E, Tatic A, Symeonidis A, Huls G, Cermak J, van de Loosdrecht AA, Garelius H, Culligan D, Macheta M, Spanoudakis M, Panagiotidis P, Krejci M, Blijlevens N, Langemeijer S, Droste J, Swinkels DW, Smith A, de Witte T; EUMDS Steering Committee. Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes. Haematologica 2018;103:69-79. [PMID: 29122992 DOI: 10.3324/haematol.2017.171884] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
29 Gupta Y, Maciorowski D, Zak SE, Jones KA, Kathayat RS, Azizi SA, Mathur R, Pearce CM, Ilc DJ, Husein H, Herbert AS, Bharti A, Rathi B, Durvasula R, Becker DP, Dickinson BC, Dye JM, Kempaiah P. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays. Methods 2021:S1046-2023(21)00015-3. [PMID: 33453392 DOI: 10.1016/j.ymeth.2021.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
30 Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013;98:1667-76. [PMID: 24186312 DOI: 10.3324/haematol.2013.084624] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 9.1] [Reference Citation Analysis]
31 Boumaiza M, Fhoula I, Carmona F, Poli M, Asperti M, Gianoncelli A, Bertuzzi M, Arosio P, Marzouki MN. Biochemical, Biophysical and Functional Characterization of an Insoluble Iron Containing Hepcidin–Ferritin Chimeric Monomer Assembled Together with Human Ferritin H/L Chains at Different Molar Ratios. CIMB 2022;44:117-27. [DOI: 10.3390/cimb44010009] [Reference Citation Analysis]
32 Maysinger D, Lalancette-hébert M, Ji J, Jabbour K, Dernedde J, Silberreis K, Haag R, Kriz J. Dendritic polyglycerols are modulators of microglia-astrocyte crosstalk. Future Neurology 2019;14:FNL31. [DOI: 10.2217/fnl-2019-0008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
33 Babitt JL, Lin HY. BuMPing iron with modified heparins. Blood 2014;123:1440-1. [PMID: 24627550 DOI: 10.1182/blood-2014-01-549519] [Reference Citation Analysis]
34 Yokoro M, Nakayama Y, Yamagishi SI, Ando R, Sugiyama M, Ito S, Yano J, Taguchi K, Kaida Y, Saigusa D, Kimoto M, Abe T, Ueda S, Fukami K. Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia. J Am Soc Nephrol 2017;28:2670-80. [PMID: 28600471 DOI: 10.1681/ASN.2016111184] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
35 Poli M, Asperti M, Ruzzenenti P, Naggi A, Arosio P. Non-Anticoagulant Heparins Are Hepcidin Antagonists for the Treatment of Anemia. Molecules 2017;22:E598. [PMID: 28397746 DOI: 10.3390/molecules22040598] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
36 Hawula ZJ, Wallace DF, Subramaniam VN, Rishi G. Therapeutic Advances in Regulating the Hepcidin/Ferroportin Axis. Pharmaceuticals (Basel) 2019;12:E170. [PMID: 31775259 DOI: 10.3390/ph12040170] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
37 Garasto S, Fusco S, Onder G, Sganga F, Mammarella F, Volpato S, Ruggiero C, Abbatecola AM, Lattanzio F, Corsonello A. Inappropriate prescription of low molecular weight heparins for thromboprophylaxis among older hospitalized patients. Aging Clin Exp Res 2017;29:483-90. [DOI: 10.1007/s40520-016-0571-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
38 Sagar P, Angmo S, Sandhir R, Rishi V, Yadav H, Singhal NK. Effect of hepcidin antagonists on anemia during inflammatory disorders. Pharmacol Ther 2021;226:107877. [PMID: 33895185 DOI: 10.1016/j.pharmthera.2021.107877] [Reference Citation Analysis]
39 Farajdokht F, Soleimani M, Mehrpouya S, Barati M, Nahavandi A. The role of hepcidin in chronic mild stress-induced depression. Neurosci Lett 2015;588:120-4. [PMID: 25576700 DOI: 10.1016/j.neulet.2015.01.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
40 Angmo S, Tripathi N, Abbat S, Sharma S, Singh SS, Halder A, Yadav K, Shukla G, Sandhir R, Rishi V, Bharatam PV, Yadav H, Singhal NK. Identification of Guanosine 5'-diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/Stat-3 Pathway. Sci Rep 2017;7:40097. [PMID: 28054602 DOI: 10.1038/srep40097] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
41 Banerjee S, Datta R. Leishmania infection triggers hepcidin-mediated proteasomal degradation of Nramp1 to increase phagolysosomal iron availability. Cell Microbiol 2020;22:e13253. [PMID: 32827218 DOI: 10.1111/cmi.13253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Boshuizen M, van Bruggen R, Zaat SA, Schultz MJ, Aguilera E, Motos A, Senussi T, Idone FA, Pelosi P, Torres A, Bassi GL, Juffermans NP. Development of a model for anemia of inflammation that is relevant to critical care. Intensive Care Med Exp 2019;7:47. [PMID: 31346819 DOI: 10.1186/s40635-019-0261-2] [Reference Citation Analysis]
43 Zhang S, Chen Y, Guo W, Yuan L, Zhang D, Xu Y, Nemeth E, Ganz T, Liu S. Disordered hepcidin-ferroportin signaling promotes breast cancer growth. Cell Signal 2014;26:2539-50. [PMID: 25093806 DOI: 10.1016/j.cellsig.2014.07.029] [Cited by in Crossref: 73] [Cited by in F6Publishing: 70] [Article Influence: 9.1] [Reference Citation Analysis]
44 Pfeifhofer-Obermair C, Tymoszuk P, Petzer V, Weiss G, Nairz M. Iron in the Tumor Microenvironment-Connecting the Dots. Front Oncol 2018;8:549. [PMID: 30534534 DOI: 10.3389/fonc.2018.00549] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 11.0] [Reference Citation Analysis]
45 Verma S, Cherayil BJ. Iron and inflammation - the gut reaction. Metallomics 2017;9:101-11. [PMID: 28067386 DOI: 10.1039/c6mt00282j] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
46 Abreu R, Essler L, Loy A, Quinn F, Giri P. Heparin inhibits intracellular Mycobacterium tuberculosis bacterial replication by reducing iron levels in human macrophages. Sci Rep 2018;8:7296. [PMID: 29740038 DOI: 10.1038/s41598-018-25480-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
47 Xue D, He X, Zhou C. Serum hepcidin level correlates with hyperlipidemia status in patients following allograft renal transplantation. Transplant Proc 2014;46:156-9. [PMID: 24507043 DOI: 10.1016/j.transproceed.2013.06.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
48 Ehsani S. COVID-19 and iron dysregulation: distant sequence similarity between hepcidin and the novel coronavirus spike glycoprotein. Biol Direct 2020;15:19. [PMID: 33066821 DOI: 10.1186/s13062-020-00275-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
49 Camaschella C. Iron and hepcidin: a story of recycling and balance. Hematology Am Soc Hematol Educ Program. 2013;2013:1-8. [PMID: 24319154 DOI: 10.1182/asheducation-2013.1.1] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
50 Cassinelli G, Naggi A. Old and new applications of non-anticoagulant heparin. Int J Cardiol 2016;212 Suppl 1:S14-21. [PMID: 27264866 DOI: 10.1016/S0167-5273(16)12004-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 8.4] [Reference Citation Analysis]
51 Canavesi E, Alfieri C, Pelusi S, Valenti L. Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease. World J Nephrol 2012; 1(6): 166-176 [PMID: 24175256 DOI: 10.5527/wjn.v1.i6.166] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
52 Vela D. Hepcidin, an emerging and important player in brain iron homeostasis. J Transl Med 2018;16:25. [PMID: 29415739 DOI: 10.1186/s12967-018-1399-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 9.3] [Reference Citation Analysis]
53 Wang M, Tang W, Xin H, Zhu YZ. S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway. PLoS One 2016;11:e0163289. [PMID: 27649298 DOI: 10.1371/journal.pone.0163289] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
54 Wiciński M, Liczner G, Cadelski K, Kołnierzak T, Nowaczewska M, Malinowski B. Anemia of Chronic Diseases: Wider Diagnostics-Better Treatment? Nutrients 2020;12:E1784. [PMID: 32560029 DOI: 10.3390/nu12061784] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
55 Reichert CO, da Cunha J, Levy D, Maselli LMF, Bydlowski SP, Spada C. Hepcidin: Homeostasis and Diseases Related to Iron Metabolism. Acta Haematol 2017;137:220-36. [DOI: 10.1159/000471838] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
56 Atkins JL, Barrows E, Byzek SA, Lee CH, Keesee J, Edwards A, Oliver JD 3rd. Regional citrate anticoagulation for hemorrhage experiments in rats. J Surg Res 2013;179:e197-202. [PMID: 22504133 DOI: 10.1016/j.jss.2012.02.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
57 Blanchette NL, Manz DH, Torti FM, Torti SV. Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev Hematol 2016;9:169-86. [PMID: 26669208 DOI: 10.1586/17474086.2016.1124757] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
58 Agoro R, Mura C. Iron Supplementation Therapy, A Friend and Foe of Mycobacterial Infections? Pharmaceuticals (Basel) 2019;12:E75. [PMID: 31108902 DOI: 10.3390/ph12020075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
59 Katsarou A, Pantopoulos K. Hepcidin Therapeutics. Pharmaceuticals (Basel) 2018;11:E127. [PMID: 30469435 DOI: 10.3390/ph11040127] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
60 Rochette L, Gudjoncik A, Guenancia C, Zeller M, Cottin Y, Vergely C. The iron-regulatory hormone hepcidin: A possible therapeutic target? Pharmacology & Therapeutics 2015;146:35-52. [DOI: 10.1016/j.pharmthera.2014.09.004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
61 Zhao N, Zhang AS, Enns CA. Iron regulation by hepcidin. J Clin Invest 2013;123:2337-43. [PMID: 23722909 DOI: 10.1172/JCI67225] [Cited by in Crossref: 123] [Cited by in F6Publishing: 56] [Article Influence: 13.7] [Reference Citation Analysis]
62 Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Targets 2019;23:407-21. [PMID: 30907175 DOI: 10.1080/14728222.2019.1599358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
63 Yin X, Wu Q, Monga J, Xie E, Wang H, Wang S, Zhang H, Wang ZY, Zhou T, Shi Y, Rogers J, Lin H, Min J, Wang F. HDAC1 Governs Iron Homeostasis Independent of Histone Deacetylation in Iron-Overload Murine Models. Antioxid Redox Signal 2018;28:1224-37. [PMID: 29113455 DOI: 10.1089/ars.2017.7161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
64 Santini V, Girelli D, Sanna A, Martinelli N, Duca L, Campostrini N, Cortelezzi A, Corbella M, Bosi A, Reda G. Hepcidin levels and their determinants in different types of myelodysplastic syndromes. PLoS One. 2011;6:e23109. [PMID: 21886780 DOI: 10.1371/journal.pone.0023109] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 6.0] [Reference Citation Analysis]
65 McClung JP. Nutrition is medicine: dietary inhibition of hepcidin expression. Br J Nutr 2014;111:1145-6. [PMID: 24503035 DOI: 10.1017/S0007114513004327] [Reference Citation Analysis]
66 Finberg KE. Regulation of systemic iron homeostasis. Curr Opin Hematol. 2013;20:208-214. [PMID: 23426198 DOI: 10.1097/moh.0b013e32835f5a47] [Cited by in Crossref: 45] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
67 Begum S, Latunde-Dada GO. Anemia of Inflammation with An Emphasis on Chronic Kidney Disease. Nutrients 2019;11:E2424. [PMID: 31614529 DOI: 10.3390/nu11102424] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
68 Pirie K, Myles P, Wood E. Anemia and iron-restricted erythropoiesis in traumatic critical illness. J Trauma Acute Care Surg 2016;80:538-45. [PMID: 26670117 DOI: 10.1097/TA.0000000000000939] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
69 Słomka A, Świtońska M, Żekanowska E. Hepcidin Levels Are Increased in Patients with Acute Ischemic Stroke: Preliminary Report. J Stroke Cerebrovasc Dis 2015;24:1570-6. [PMID: 25881778 DOI: 10.1016/j.jstrokecerebrovasdis.2015.03.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
70 Liu J, Sun B, Yin H, Liu S. Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review. Medicine (Baltimore) 2016;95:e3150. [PMID: 27057839 DOI: 10.1097/MD.0000000000003150] [Cited by in Crossref: 44] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
71 Banerjee S, Katiyar P, Kumar L, Kumar V, Saini SS, Krishnan V, Sircar D, Roy P. Black pepper prevents anemia of inflammation by inhibiting hepcidin over-expression through BMP6-SMAD1/ IL6-STAT3 signaling pathway. Free Radic Biol Med 2021;168:189-202. [PMID: 33771600 DOI: 10.1016/j.freeradbiomed.2021.03.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Asperti M, Naggi A, Esposito E, Ruzzenenti P, Di Somma M, Gryzik M, Arosio P, Poli M. High Sulfation and a High Molecular Weight Are Important for Anti-hepcidin Activity of Heparin. Front Pharmacol 2015;6:316. [PMID: 26955355 DOI: 10.3389/fphar.2015.00316] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
73 Macciò A, Madeddu C. Management of anemia of inflammation in the elderly. Anemia 2012;2012:563251. [PMID: 23091709 DOI: 10.1155/2012/563251] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
74 Oryan A, Alidadi S, Moshiri A, Bigham-Sadegh A. Bone morphogenetic proteins: a powerful osteoinductive compound with non-negligible side effects and limitations. Biofactors 2014;40:459-81. [PMID: 25283434 DOI: 10.1002/biof.1177] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
75 Torti SV, Lemler E, Mueller BK, Popp A, Torti FM. Effects of Anti-repulsive Guidance Molecule C (RGMc/Hemojuvelin) Antibody on Hepcidin and Iron in Mouse Liver and Tumor Xenografts. Clin Exp Pharmacol 2016;6:223. [PMID: 28203489 DOI: 10.4172/2161-1459.1000223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
76 Murawska N, Fabisiak A, Fichna J. Anemia of Chronic Disease and Iron Deficiency Anemia in Inflammatory Bowel Diseases: Pathophysiology, Diagnosis, and Treatment. Inflamm Bowel Dis. 2016;22:1198-1208. [PMID: 26818422 DOI: 10.1097/mib.0000000000000648] [Cited by in Crossref: 34] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
77 Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117:4425-4433. [PMID: 21346250 DOI: 10.1182/blood-2011-01-258467] [Cited by in Crossref: 563] [Cited by in F6Publishing: 510] [Article Influence: 51.2] [Reference Citation Analysis]
78 Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014;29:263-73. [PMID: 24235084 DOI: 10.1093/ndt/gft443] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
79 Wang C, Fang Z, Zhu Z, Liu J, Chen H. Reciprocal regulation between hepcidin and erythropoiesis and its therapeutic application in erythroid disorders. Experimental Hematology 2017;52:24-31. [DOI: 10.1016/j.exphem.2017.05.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
80 Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol 2014;5:86. [PMID: 24808863 DOI: 10.3389/fphar.2014.00086] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 9.5] [Reference Citation Analysis]
81 Girelli D, Marchi G, Camaschella C. Anemia in the Elderly. Hemasphere 2018;2:e40. [PMID: 31723768 DOI: 10.1097/HS9.0000000000000040] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
82 Wang YS, Zhang FK. [Advances on diagnosis and treatment of anemia of inflammation]. Zhonghua Xue Ye Xue Za Zhi 2018;39:782-6. [PMID: 30369194 DOI: 10.3760/cma.j.issn.0253-2727.2018.09.017] [Reference Citation Analysis]
83 Eisenga MF, Dullaart RP, Berger SP, Sloan JH, de Vries AP, Bakker SJ, Gaillard CA. Association of hepcidin-25 with survival after kidney transplantation. Eur J Clin Invest 2016;46:994-1001. [PMID: 27696386 DOI: 10.1111/eci.12682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
84 Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis-Mechanistic Insights into Anemia of Inflammation and Its Treatment. Nutrients 2021;13:3732. [PMID: 34835988 DOI: 10.3390/nu13113732] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Kong WN, Gao G, Chang YZ. Hepcidin and sports anemia. Cell Biosci 2014;4:19. [PMID: 24731443 DOI: 10.1186/2045-3701-4-19] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
86 Vagionas D, Politou M, Kompoti M, Papadakis DD, Kostakou E, Theodoulou D, Kaniaris E, Rovina N, Koutsoukou A, Vasileiadis I. Unfractionated heparin reduces hepcidin levels in critically ill patients. Intern Med J 2021;51:797-801. [PMID: 34047020 DOI: 10.1111/imj.15317] [Reference Citation Analysis]
87 Sun CC, Vaja V, Babitt JL, Lin HY. Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation. Am J Hematol. 2012;87:392-400. [PMID: 22290531 DOI: 10.1002/ajh.23110] [Cited by in Crossref: 114] [Cited by in F6Publishing: 105] [Article Influence: 11.4] [Reference Citation Analysis]
88 Vyoral D, Jiri Petrak. Therapeutic potential of hepcidin − the master regulator of iron metabolism. Pharmacological Research 2017;115:242-54. [DOI: 10.1016/j.phrs.2016.11.010] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
89 Shibabaw T, Teferi B, Molla MD, Ayelign B. Inflammation Mediated Hepcidin-Ferroportin Pathway and Its Therapeutic Window in Breast Cancer. Breast Cancer (Dove Med Press) 2020;12:165-80. [PMID: 33116818 DOI: 10.2147/BCTT.S276404] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721-1741. [PMID: 24137020 DOI: 10.1152/physrev.00008.2013] [Cited by in Crossref: 528] [Cited by in F6Publishing: 477] [Article Influence: 58.7] [Reference Citation Analysis]
91 Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial Activity of Mesenchymal Stem Cells: Current Status and New Perspectives of Antimicrobial Peptide-Based Therapies. Front Immunol 2017;8:339. [PMID: 28424688 DOI: 10.3389/fimmu.2017.00339] [Cited by in Crossref: 94] [Cited by in F6Publishing: 91] [Article Influence: 18.8] [Reference Citation Analysis]
92 Zeidan A, Bhandari S. Anemia in Peritoneal Dialysis Patients; Iron Repletion, Current and Future Therapies. Perit Dial Int 2017;37:6-13. [PMID: 28153964 DOI: 10.3747/pdi.2016.00193] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
93 Langer AL, Ginzburg YZ. Role of hepcidin-ferroportin axis in the pathophysiology, diagnosis, and treatment of anemia of chronic inflammation. Hemodial Int 2017;21 Suppl 1:S37-46. [PMID: 28328181 DOI: 10.1111/hdi.12543] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
94 Abdel-Khalek MA, El-Barbary AM, Essa SA, Ghobashi AS. Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis. J Rheumatol 2011;38:2153-9. [PMID: 21885483 DOI: 10.3899/jrheum.110339] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
95 Ashok A, Chaudhary S, Kritikos AE, Kang MH, McDonald D, Rhee DJ, Singh N. TGFβ2-Hepcidin Feed-Forward Loop in the Trabecular Meshwork Implicates Iron in Glaucomatous Pathology. Invest Ophthalmol Vis Sci 2020;61:24. [PMID: 32182331 DOI: 10.1167/iovs.61.3.24] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
96 Arnold K, Liao YE, Liu J. Potential Use of Anti-Inflammatory Synthetic Heparan Sulfate to Attenuate Liver Damage. Biomedicines 2020;8:E503. [PMID: 33207634 DOI: 10.3390/biomedicines8110503] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Mu M, An P, Wu Q, Shen X, Shao D, Wang H, Zhang Y, Zhang S, Yao H, Min J, Wang F. The dietary flavonoid myricetin regulates iron homeostasis by suppressing hepcidin expression. J Nutr Biochem 2016;30:53-61. [PMID: 27012621 DOI: 10.1016/j.jnutbio.2015.10.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
98 Guo W, Schmidt PJ, Fleming MD, Bhasin S. Effects of Testosterone on Erythropoiesis in a Female Mouse Model of Anemia of Inflammation. Endocrinology 2016;157:2937-46. [PMID: 27074351 DOI: 10.1210/en.2016-1150] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]